Financial Analysis: Rubius Therapeutics (NASDAQ:RUBY) Vs. Cardiol Therapeutics (NASDAQ:CRDL)
Financial Analysis: Rubius Therapeutics (NASDAQ:RUBY) Vs. Cardiol Therapeutics (NASDAQ:CRDL)
Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Cardiol Therapeutics (NASDAQ:CRDL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, institutional ownership, profitability, earnings and risk.
納斯達克(股票代碼：Ruby-GET)和心臟治療公司(納斯達克：CRDL-GET)都是小盤醫療公司，但哪隻股票更具優勢？我們將根據分析師的建議、估值、股息、機構所有權、盈利能力、收益和風險對這兩家公司進行比較。
Institutional and Insider Ownership
機構和內部人持股
76.1% of Rubius Therapeutics shares are owned by institutional investors. Comparatively, 7.5% of Cardiol Therapeutics shares are owned by institutional investors. 52.8% of Rubius Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Rubius治療公司76.1%的股份由機構投資者持有。相比之下，心臟治療公司7.5%的股份由機構投資者持有。Rubius治療公司52.8%的股份由內部人士持有。相比之下，心臟治療公司5.3%的股份由內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金管理公司相信，一家公司的長期表現將好於大盤。
Volatility and Risk
波動性和風險
Rubius Therapeutics has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of -0.13, suggesting that its share price is 113% less volatile than the S&P 500.
Rubius Treateutics的貝塔係數為2.51，這表明其股價的波動性比標準普爾500指數高出151%。相比之下，心臟治療公司的貝塔係數為-0.13，這表明其股價的波動性比標準普爾500指數低113%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and price targets for Rubius Therapeutics and Cardiol Therapeutics, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Rubius治療公司和心臟治療公司最近的評級和目標價細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rubius Therapeutics | 0 | 3 | 1 | 0 | 2.25 |
| Cardiol Therapeutics | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Rubius治療公司 | 0 | 3 | 1 | 0 | 2.25 |
| 心臟治療學 | 0 | 0 | 0 | 0 | 不適用 |
Rubius Therapeutics presently has a consensus price target of $5.00, suggesting a potential upside of 5,924.10%. Cardiol Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 684.47%. Given Rubius Therapeutics' higher probable upside, equities research analysts plainly believe Rubius Therapeutics is more favorable than Cardiol Therapeutics.
Rubius治療公司目前的共識目標價為5.00美元，這意味着潛在的上漲幅度為5924.10%。心臟治療公司的共識目標價為4美元，這意味着潛在的上漲684.47%。鑑於Rubius治療公司更有可能上行，股票研究分析師顯然認為Rubius治療公司比心臟治療公司更有利。
Valuation and Earnings
估值和收益
This table compares Rubius Therapeutics and Cardiol Therapeutics' top-line revenue, earnings per share (EPS) and valuation.
下表比較了Rubius治療公司和心臟治療公司的營收、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rubius Therapeutics | N/A | N/A | -$179.67 million | ($2.38) | -0.03 |
| Cardiol Therapeutics | $60,000.00 | 544.74 | -$25.24 million | ($0.38) | -1.34 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Rubius治療公司 | 不適用 | 不適用 | -1.7967億美元 | ($2.38) | -0.03 |
| 心臟治療學 | $60,000.00 | 544.74 | -2,524萬美元 | ($0.38) | -1.34 |
Cardiol Therapeutics has higher revenue and earnings than Rubius Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
心臟治療公司的收入和收益比Rubius治療公司高。心臟治療公司的市盈率低於Rubius治療公司，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
This table compares Rubius Therapeutics and Cardiol Therapeutics' net margins, return on equity and return on assets.
下表比較了Rubius治療公司和心臟治療公司的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Rubius Therapeutics | N/A | -212.29% | -86.74% |
| Cardiol Therapeutics | N/A | -44.32% | -38.18% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Rubius治療公司 | 不適用 | -212.29% | -86.74% |
| 心臟治療學 | 不適用 | -44.32% | -38.18% |
Summary
摘要
Rubius Therapeutics beats Cardiol Therapeutics on 6 of the 11 factors compared between the two stocks.
在兩隻股票之間的11個因素中，Rubius治療公司在6個因素上擊敗了心臟治療公司。
About Rubius Therapeutics
關於Rubius Treateutics
(Get Rating)
(獲取評級)
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan on April 26, 2013 and is headquartered in Foxboro, MA.
Rubius Treateutics，Inc.致力於開發治療癌症、自身免疫性疾病、血友病以及傳染病和代謝性疾病的紅細胞治療藥物。該公司由Avak Kahvekin、Jordan i Mata-Fink和Noubar Afeyan於2013年4月26日創立，總部位於馬薩諸塞州福克斯伯勒。
About Cardiol Therapeutics
關於心臟治療學
(Get Rating)
(獲取評級)
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ""ARCHER"" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.
心臟治療公司是一家臨牀階段的生命科學公司，專注於心髒疾病治療的抗炎和抗纖維化療法的研究和臨牀。它的主要候選產品HearolRx是一種正在臨牀開發用於心臟病的藥物製造的口服大麻二醇製劑。該公司正在進行臨牀研究，以評估HearolRx治療影響心臟的疾病的有效性和安全性：治療急性心肌炎的第二階段多國、隨機、雙盲、安慰劑對照試驗(“Archer”試驗)；以及第二階段多中心開放標籤試驗，治療複發性心包炎。它還參與開發一種用於治療心力衰竭的新型皮下給藥大麻二醇藥物配方。該公司由David·埃爾斯利、埃爾登·史密斯和安東尼·博爾頓於2017年1月19日創立，總部位於加拿大奧克維爾。
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Rubius Treateutics Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Rubius Treeutics和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。